Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China

doi:10.3390/ph17070900

科研成果详情

题名	Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China
作者	Zhang, Jiafeng 1; Sun, Baochang 2; Sheng, Zihang 3,4; Ding, Xiaobei 1; Fan, Qin 1; Huang, Gang 1,5; Guo, Zhihong 1; Zhong, Ping 6; Liao, Lingjie 7; Xing, Hui 7; Xia, Yan 1; Chai, Chengliang 1; Jiang, Jianmin 1
发表日期	2024-07
发表期刊	PHARMACEUTICALS 影响因子和分区
语种	英语
原始文献类型	Article
关键词	HIV-1 pre-treatment drug resistance nucleoside reverse transcriptase inhibitor non-nucleoside reverse transcriptase inhibitor protease inhibitor integrase strand transfer inhibitor
其他关键词	TREATMENT-NAIVE PATIENTS ; INHIBITOR RESISTANCE ; GENETIC DIVERSITY ; INFECTION
摘要	HIV drug resistance compromises the ability of anti-retroviral therapy (ART) to suppress viral replication, resulting in treatment failure. This study investigates the prevalence of pre-treatment drug resistance (PDR) in newly diagnosed individuals in a prosperous city (Wenzhou) in Southeastern China. A cross-sectional investigation was carried out among 473 newly diagnosed ART-naive HIV-1-infected individuals between January and December 2022. The protease-reverse transcriptase (PR-RT) region and integrase (IN) region of HIV-1 were amplified by two separately nested PCRs, followed by sequencing. Drug resistance mutations (DRMs) and drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and integrase strand transfer inhibitors (INSTIs) were analyzed. The PDR prevalence was 6.5% [95% CI: 4.4-9.1] for any anti-retroviral drug, 0.9% [95% CI: 0.3-2.3] for NRTIs, 4.1% [95% CI: 2.5-6.5] for NNRTIs, 1.8% [95% CI: 0.8-3.6] for PIs and 0.5% [95% CI: 0.1-1.8] for INSTIs. According to the subtyping results of the PR-RT region, 11 different subtypes and 31 unique recombinant forms (URFs) were found. CRF07_BC was the dominant subtype (53.7%, 233/434), followed by CRF01_AE (25.3%, 110/434). V179D (1.6%) and K103N (1.4%) were the most predominant types of NNRTI DRMs. Q58E (1.2%) and M184V (0.7%) were the most frequent PI DRMs and NRTI DRMs, respectively. The INSTI-related DRMs Y143S (causes high-level resistance to RAL) and G163K (causes low-level resistance to EVG and RAL) were found in one patient each. Given the relatively high PDR prevalence of NNRTI (4.1%), non-NNRTI-based ART may be preferred in the future. It is recommended to include genotypic resistance testing before starting ART in regions where feasible.
资助项目	National key research and development program of China [2022YFC2305201]; Basic Scientific Research Project of Wenzhou Science and Technology Bureau [Y2020542]
出版者	MDPI
ISSN	1424-8247
EISSN	1424-8247
卷号	17 期号:7
DOI	10.3390/ph17070900
页数	10
WOS类目	Chemistry, Medicinal ; Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
WOS记录号	WOS:001277022200001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	3906575
SCOPUSEID	2-s2.0-85199882559
通讯作者地址	[Chai, Chengliang;Jiang, Jianmin]Zhejiang Prov Ctr Dis Control & Prevent, Dept HIV AIDS Control & Prevent, Hangzhou 310051, Peoples R China.
Scopus学科分类	Molecular Medicine;Pharmaceutical Science;Drug Discovery
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/216704
专题	检验医学院（生命科学学院、生物学实验教学中心）
通讯作者	Chai, Chengliang; Jiang, Jianmin
作者单位	1.Zhejiang Prov Ctr Dis Control & Prevent, Dept HIV AIDS Control & Prevent, Hangzhou 310051, Peoples R China; 2.Wenzhou Municipal Ctr Dis Control & Prevent, Dept Microbiol Test, Wenzhou 325001, Peoples R China; 3.Wenzhou Med Univ, Sch Lab Med, Sch Life Sci, Wenzhou 325035, Peoples R China; 4.Wenzhou Med Univ, Sch Life Sci, Wenzhou 325035, Peoples R China; 5.Ningbo Univ, Hlth Sci Ctr, Ningbo 315211, Peoples R China; 6.Shanghai Municipal Ctr Dis Control & Prevent, Shanghai 200336, Peoples R China; 7.Natl Ctr AIDS STD Control & Prevent NCAIDS, Div Virol & Immunol, Beijing 102206, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Jiafeng,Sun, Baochang,Sheng, Zihang,et al. Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China[J]. PHARMACEUTICALS,2024,17(7).
APA	Zhang, Jiafeng., Sun, Baochang., Sheng, Zihang., Ding, Xiaobei., Fan, Qin., ... & Jiang, Jianmin. (2024). Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China. PHARMACEUTICALS, 17(7).
MLA	Zhang, Jiafeng,et al."Full-Spectrum Surveillance of Pre-Treatment HIV Drug Resistance in Southeastern China".PHARMACEUTICALS 17.7(2024).